Literature DB >> 18709334

MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-beta1.

Scott L Kominsky1, Michele Doucet, Margaret Thorpe, Kristy L Weber.   

Abstract

Bone metastasis occurs frequently in renal cell carcinoma (RCC) patients causing significant morbidity by stimulating excessive osteolysis, yet the mechanisms responsible have been little studied. Matrix metalloproteinases (MMPs) are over-expressed in many cancer types and are believed to play a role in bone metastasis, however, the expression of MMPs in RCC bone metastasis (RBM) has not been investigated. Due to their ability to degrade the main component of organic bone matrix, type I collagen, we investigated the expression of MMP-1, -2, -8, -9, and -13 in RBM. By quantitative (q)RT-PCR, expression of MMP-13 was significantly increased in RBM tissues relative to that in RCC and adjacent normal kidney while no differences in the expression of MMP-1, -2, -8, or -9 mRNA were observed. Correspondingly, increased expression of MMP-13 protein was also observed in RBM relative to RCC by immunohistochemical analysis. Intriguingly, the expression of MMP-13 in the human RBM cell line RBM1-IT4 was stimulated by TGF-beta1, a growth factor abundant in the bone microenvironment and known to promote RBM-induced osteolysis in animals. Exposure of RBM1-IT4 cells to TGF-beta1 increased MMP-13 mRNA levels as well as the latent and active forms of MMP-13 protein. Further, stable expression of a dominant-negative TGF-beta type II receptor in RBM1-IT4 cells inhibited MMP-13 expression following TGF-beta1 exposure. These data suggest that MMP-13 expression is elevated in RBM relative to primary RCC and adjacent normal kidney, and is regulated at the cellular level by TGF-beta1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18709334     DOI: 10.1007/s10585-008-9202-2

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  17 in total

1.  The skeletal metastatic complications of renal cell carcinoma.

Authors:  J Zekri; N Ahmed; R E Coleman; B W Hancock
Journal:  Int J Oncol       Date:  2001-08       Impact factor: 5.650

2.  Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption.

Authors:  K Kusano; C Miyaura; M Inada; T Tamura; A Ito; H Nagase; K Kamoi; T Suda
Journal:  Endocrinology       Date:  1998-03       Impact factor: 4.736

3.  Transcriptional activation of collagenase-3 by transforming growth factor-beta1 is via MAPK and Smad pathways in human breast cancer cells.

Authors:  Nagarajan Selvamurugan; Ziawei Fung; Nicola C Partridge
Journal:  FEBS Lett       Date:  2002-12-04       Impact factor: 4.124

4.  Initiation of osteoclast bone resorption by interstitial collagenase.

Authors:  L S Holliday; H G Welgus; C J Fliszar; G M Veith; J J Jeffrey; S L Gluck
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

Review 5.  Regulation of matrix metalloproteinase gene expression.

Authors:  Chunhong Yan; Douglas D Boyd
Journal:  J Cell Physiol       Date:  2007-04       Impact factor: 6.384

6.  A multigenic program mediating breast cancer metastasis to bone.

Authors:  Yibin Kang; Peter M Siegel; Weiping Shu; Maria Drobnjak; Sanna M Kakonen; Carlos Cordón-Cardo; Theresa A Guise; Joan Massagué
Journal:  Cancer Cell       Date:  2003-06       Impact factor: 31.743

7.  Characterization of a renal cell carcinoma cell line derived from a human bone metastasis and establishment of an experimental nude mouse model.

Authors:  Kristy L Weber; Sen Pathak; Asha S Multani; Janet E Price
Journal:  J Urol       Date:  2002-08       Impact factor: 7.450

8.  Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments.

Authors:  R T Aimes; J P Quigley
Journal:  J Biol Chem       Date:  1995-03-17       Impact factor: 5.157

9.  Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate.

Authors:  S Koop; I C MacDonald; K Luzzi; E E Schmidt; V L Morris; M Grattan; R Khokha; A F Chambers; A C Groom
Journal:  Cancer Res       Date:  1995-06-15       Impact factor: 12.701

10.  Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic contact.

Authors:  T J Chambers; K Fuller
Journal:  J Cell Sci       Date:  1985-06       Impact factor: 5.285

View more
  17 in total

1.  Collagenase expression and activity in the stromal cells from giant cell tumour of bone.

Authors:  Robert W Cowan; Isabella W Y Mak; Nigel Colterjohn; Gurmit Singh; Michelle Ghert
Journal:  Bone       Date:  2009-02-12       Impact factor: 4.398

2.  Unique angiogenic and vasculogenic properties of renal cell carcinoma in a xenograft model of bone metastasis are associated with high levels of vegf-a and decreased ang-1 expression.

Authors:  Chao Xie; Edward M Schwarz; Erik R Sampson; Robinder S Dhillon; Dan Li; Regis J O'Keefe; Wakenda Tyler
Journal:  J Orthop Res       Date:  2011-08-01       Impact factor: 3.494

Review 3.  Dichotomous roles of TGF-β in human cancer.

Authors:  Jennifer J Huang; Gerard C Blobe
Journal:  Biochem Soc Trans       Date:  2016-10-15       Impact factor: 5.407

4.  Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors.

Authors:  Tressa M Allington; Amy J Galliher-Beckley; William P Schiemann
Journal:  FASEB J       Date:  2009-08-18       Impact factor: 5.191

Review 5.  Metastasis review: from bench to bedside.

Authors:  Ali Mohammad Alizadeh; Sadaf Shiri; Sadaf Farsinejad
Journal:  Tumour Biol       Date:  2014-08-08

6.  Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?

Authors:  P Ivanyi; J Koenig; A Trummer; J F Busch; C Seidel; C W Reuter; A Ganser; V Grünwald
Journal:  World J Urol       Date:  2015-11-19       Impact factor: 4.226

7.  An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer.

Authors:  Manisha Shah; Dexing Huang; Tony Blick; Andrea Connor; Lawrence A Reiter; Joel R Hardink; Conor C Lynch; Mark Waltham; Erik W Thompson
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

8.  ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signaling.

Authors:  Tetsuro Masuda; Motoyoshi Endo; Yutaka Yamamoto; Haruki Odagiri; Tsuyoshi Kadomatsu; Takayuki Nakamura; Hironori Tanoue; Hitoshi Ito; Masaki Yugami; Keishi Miyata; Jun Morinaga; Haruki Horiguchi; Ikuyo Motokawa; Kazutoyo Terada; Masaki Suimye Morioka; Ichiro Manabe; Hirotaka Iwase; Hiroshi Mizuta; Yuichi Oike
Journal:  Sci Rep       Date:  2015-03-16       Impact factor: 4.379

9.  Host and tumor derived MMP13 regulate extravasation and establishment of colorectal metastases in the liver.

Authors:  Alisha M Mendonsa; Michael N VanSaun; Alessandro Ustione; David W Piston; Barbara M Fingleton; David Lee Gorden
Journal:  Mol Cancer       Date:  2015-02-22       Impact factor: 27.401

10.  Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.

Authors:  Attila Szendrői; A Marcell Szász; Magdolna Kardos; Anna-Mária Tőkés; Roni Idan; Miklós Szűcs; Janina Kulka; Péter Nyirády; Miklós Szendrői; Zoltán Szállási; Balázs Győrffy; József Tímár
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.